K
Keita Fujikawa
Researcher at Nagasaki University
Publications - 95
Citations - 2644
Keita Fujikawa is an academic researcher from Nagasaki University. The author has contributed to research in topics: Rheumatoid arthritis & Tocilizumab. The author has an hindex of 24, co-authored 95 publications receiving 2234 citations.
Papers
More filters
Journal ArticleDOI
Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
Yasuhito Hamaguchi,Manabu Fujimoto,Takashi Matsushita,Kenzo Kaji,Kazuhiro Komura,Minoru Hasegawa,Masanari Kodera,Eiji Muroi,Keita Fujikawa,Mariko Seishima,Hidehiro Yamada,Ryo Yamada,Shinichi Sato,Kazuhiko Takehara,Masataka Kuwana +14 more
TL;DR: Identification of individual anti-ARS Abs is beneficial to define this rather homogeneous subset and to predict clinical outcomes within the “anti-synthetase syndrome.”
Journal ArticleDOI
Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study.
Yasuhito Hamaguchi,Masataka Kuwana,Kana Hoshino,Minoru Hasegawa,Kenzo Kaji,Takashi Matsushita,Kazuhiro Komura,Motonobu Nakamura,Masanari Kodera,Norihiro Suga,Akira Higashi,Koji Ogusu,Kiyohiro Tsutsui,Akira Furusaki,Hiroshi Tanabe,Shunsuke Sasaoka,Yoshinao Muro,Mika Yoshikawa,Naoko Ishiguro,Masahiro Ayano,Eiji Muroi,Keita Fujikawa,Yukihiro Umeda,Masaaki Kawase,Eriko Mabuchi,Yoshihide Asano,Kinuyo Sodemoto,Mariko Seishima,Hidehiro Yamada,Shinichi Sato,Kazuhiko Takehara,Manabu Fujimoto +31 more
TL;DR: Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.
Journal ArticleDOI
Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
Manabu Fujimoto,Yasuhito Hamaguchi,Kenzo Kaji,Takashi Matsushita,Yuki Ichimura,Masanari Kodera,Naoko Ishiguro,Ikuko Ueda-Hayakawa,Yoshihide Asano,Fumihide Ogawa,Keita Fujikawa,Takuya Miyagi,Eriko Mabuchi,Kenji Hirose,Narihiro Akimoto,Naohito Hatta,Kiyohiro Tsutsui,Akira Higashi,Atsuyuki Igarashi,Mariko Seishima,Minoru Hasegawa,Kazuhiko Takehara +21 more
TL;DR: To identify the 140-kd autoantigen recognized by anti-155/140 autoantibodies that are associated with adult cancer-associated dermatomyositis and juvenile DM and to determine the clinical relevance of anti- 155/140 antibodies in a large cohort is determined.
Journal ArticleDOI
A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies
Mami Tamai,Atsushi Kawakami,Masataka Uetani,Shoichiro Takao,Kazuhiko Arima,Naoki Iwamoto,Keita Fujikawa,Toshiyuki Aramaki,Shin-ya Kawashiri,Kunihiro Ichinose,Makoto Kamachi,Hideki Nakamura,Tomoki Origuchi,Hiroaki Ida,Kiyoshi Aoyagi,Katsumi Eguchi +15 more
TL;DR: MRI-proven early joint damage in conjunction with serologic autoantibodies is efficient in predicting progression from UA to RA, and can be used to identify patients who would benefit from early treatment with disease-modifying antirheumatic drugs.
Journal ArticleDOI
Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
Shin-ya Kawashiri,Atsushi Kawakami,Satoshi Yamasaki,Takahiro Imazato,Naoki Iwamoto,Keita Fujikawa,Toshiyuki Aramaki,Mami Tamai,Hideki Nakamura,Hiroaki Ida,Tomoki Origuchi,Yukitaka Ueki,Katsumi Eguchi +12 more
TL;DR: In one patient, whose serum level of TCZ was not detected after 3 months of the treatment, the absence of the increment in serum levels of Apo A-1 and A-2 in the patient was remarkable, and may raise an important issue to evaluate the impact of these alternations in lipid metabolism for longer periods in RA patients treated with TCZ.